Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Zobrazit další vydání (1)

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

Celý popis

Podrobná bibliografie
Hlavní autoři: Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
Médium: Journal article
Vydáno: 2013

Podobné jednotky

Podobné jednotky